Clearmind Medicine (Clearmind Medicine) Interest Expense : $0.00 Mil (TTM As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Clearmind Medicine's interest expense for the three months ended in Jan. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jan. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Clearmind Medicine's Operating Income for the three months ended in Jan. 2024 was $ -1.38 Mil. Clearmind Medicine's Interest Expense for the three months ended in Jan. 2024 was $ 0.00 Mil. GuruFocus does not calculate Clearmind Medicine's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Clearmind Medicine Interest Expense Historical Data

The historical data trend for Clearmind Medicine's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Interest Expense Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Interest Expense

Get a 7-Day Free Trial

-0.01

Clearmind Medicine Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Clearmind Medicine Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Clearmind Medicine (NAS:CMND) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Clearmind Medicine's Interest Expense for the three months ended in Jan. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Jan. 2024 was $-1.38 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jan. 2024 was $0.03 Mil.

Clearmind Medicine's Interest Coverage for the quarter that ended in Jan. 2024 is calculated as

GuruFocus does not calculate Clearmind Medicine's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Clearmind Medicine Inc has enough cash to cover all of its debt. Its financial situation is stable.

Clearmind Medicine (Clearmind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

CWY0:Germany CWY0:Germany CMND:Canada

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.